Verastem: Planning The PDUFA Run-Up
Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application
Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...
Hosted on MSN2d
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...
FDA To Decide On Verastem's Avutometinib & Defactinib For A Subtype Of Serous Ovarian Cancer In June
Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
FDA accepts Verastem NDA for ovarian cancer drug combo
Verastem (NASDAQ:VSTM) said the FDA has accepted its New Drug Application for accelerated approval of its drugs avutometinib ...
bovnews2d
A Big Leap Forward: Verastem Oncology’s (VSTM) Stock Skyrockets Amid Breakthrough Cancer News
When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...
bovnews2d
What’s Causing Verastem Inc (VSTM) Stock’s 76.15% Jump Over the Last Six Months?
Verastem Inc (VSTM) stock saw a modest uptick, ending the day at $5.17 which represents a slight increase of $1.50 or 40.87% from the prior close of $3.67. The stock opened at $4.91 and touched a low ...
kalkinemedia2d
Verastem Oncology (NASDAQ: VSTM) Announces FDA Acceptance and Priority Review of NDA for Avutometinib and Defactinib
Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.